[Comparison of the effectiveness of intra-arterial and intravenous administration of buflomedil in patients with intermittent claudication].
Buflomedil is a vasoactive agent widely used in the treatment of peripheral arterial disease. 42 patients with peripheral obliterative arterial disease (POAD) in the intermittent claudication stage were treated in a randomized controlled study with 200 mg Buflomedil either intraarterially or intravenously. The infusions with this vasoactive agent were given daily for 15 days, on weekends the patients took 300 mg Buflomedil orally twice. Painfree walking distance on a treadmill was below 75 m at entrance. The treatment was controlled by treadmill test and systolic blood pressure gradients. The painfree walking distance was improved in the i.v. group from 38.7 to 91.7 m (+137%); in the i.a. group from 43.4 to 126m (+190%). There was a significant difference between the increases of painfree walking distances in both groups. No changes of doppler gradients occured. The result of this controlled study confirm that i.a. administered Buflomedil increases painfree walking distances more pronounced than i.v. infusions in patients with intermittent claudication due to POAD.